GF FUND MANAGEMENT CO LTD CSI HONG KONG BRAND NAME DRUG INDEX ETFGF FUND MANAGEMENT CO LTD CSI HONG KONG BRAND NAME DRUG INDEX ETFGF FUND MANAGEMENT CO LTD CSI HONG KONG BRAND NAME DRUG INDEX ETF

GF FUND MANAGEMENT CO LTD CSI HONG KONG BRAND NAME DRUG INDEX ETF

No trades
See on Supercharts

Key stats


Assets under management (AUM)
Fund flows (1Y)
Dividend yield (indicated)
Discount/Premium to NAV
Shares outstanding
Expense ratio
0.60%

About GF FUND MANAGEMENT CO LTD CSI HONG KONG BRAND NAME DRUG INDEX ETF


Brand
GF Fund
Inception date
Jul 1, 2022
Structure
Open-Ended Fund
Index tracked
CSI Hong Kong Innovative Drug Index - CNY - Benchmark TR Gross
Replication method
Physical
Management style
Passive
Dividend treatment
Distributes
Primary advisor
GF Fund Management Co., Ltd.
ISIN
CNE100005BG9
Tightly track the target index, pursue the minimization of tracking deviation and tracking err. The fund strives to control the absolute value of the daily average tracking deviation between the net value growth rate of the investment portfolio & the performance benchmark is less than 0.2%, & the annualized tracking deviation is less than 0.2%.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Pharmaceuticals
Strategy
Vanilla
Geography
China
Weighting scheme
Market cap
Selection criteria
Market cap

Returns


1 month3 monthsYear to date1 year3 years5 years
Price performance
NAV total return

What's in the fund


As of December 31, 2024
Exposure type
StocksBonds, Cash & Other
Health Technology
Stocks93.96%
Health Technology92.61%
Commercial Services1.34%
Bonds, Cash & Other6.04%
Cash6.04%
Stock breakdown by region
9%90%
Asia90.24%
North America9.76%
Latin America0.00%
Europe0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings

Dividends


Dividend payout history

Assets under management (AUM)



Fund Flows



Frequently Asked Questions


513120 invests in stocks. The fund's major sectors are Health Technology, with 92.61% stocks, and Commercial Services, with 1.34% of the basket. The assets are mostly located in the Asia region.
513120 top holdings are Innovent Biologics, Inc. and Wuxi Biologics (Cayman) Inc., occupying 9.67% and 9.55% of the portfolio correspondingly.
No, 513120 doesn't pay dividends to its holders.
513120 shares are issued by GF Securities Co., Ltd. under the brand GF Fund. The ETF was launched on Jul 1, 2022, and its management style is Passive.
513120 expense ratio is 0.60% meaning you'd have to pay 0.60% of your investment to help manage the fund.
513120 follows the CSI Hong Kong Innovative Drug Index - CNY - Benchmark TR Gross. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
513120 invests in stocks.